




Christoph Correll, MD

Dr. Christoph Correll is currently Professor of Psychiatry at Hofstra Northwell School of Medicine, New York, USA and Medical Director of the Recognition and Prevention (RAP) program at the Zucker Hillside Hospital, New York, USA. He completed his medical studies at both the Free University of Berlin in Germany, and at the Dundee University Medical School in Scotland. He is board certified in both general psychiatry and child and adolescent psychiatry, having completed both residencies at The Zucker Hillside Hospital in New York City.

Dr. Correll's research and clinical work focus on the identification, characterisation and treatment of adults and youths with severe psychiatric disorders. His areas of expertise include the prodrome, first episode, multi-episode and refractory illness phase of severe psychotic and mood disorders, including schizophrenia, bipolar disorder, major depression, as well as aggressive spectrum disorders. He further focuses on psychopharmacology and comparative effectiveness, the risk-benefit evaluation of psychotropic medications, as well as the extent and mechanisms of cardiometabolic and neuromotor adverse effects.

Dr. Correll has authored or co-authored over 400 journal articles. He has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders, is a reviewer for over 70 peer-reviewed journals and an editorial board member of 12 scientific journals. Dr. Correll is the Principal Investigator or Steering Committee member of several large, federally funded grants. He has received over 30 national and international research awards and fellowships for his work and was listed by Thomson Reuters in 2014 and 2015 as one of "The most influential scientific minds" and "top 1% cited scientists in the area of psychiatry".



Stephen Crystal, MD

Dr. Crystal is Board of Governors Professor of Health Services Research at Rutgers University, where he directs the Center for Health Services Research and the AHRQ-funded Center for Education and Research on Mental Health Therapeutics (CERTs), a federally-funded center that develops and analyzes evidence on safe and judicious use of psychotropic medications, and works with stakeholders around the country to help them assess and utilize evidence on appropriate use; identify and implement best practices; make more effective use of data; and develop and effectively utilize quality measures. The Center aims to serve as an objective and unbiased resource for public agencies and other stakeholders in assessing and utilizing evidence on medication safety, effectiveness and appropriate use.

Dr. Crystal's research work on mental health services; safety and effectiveness of prescription medication; children's mental health; Medicaid policy; quality improvement; and other areas of health policy and pharmacoepidemiology has had national impact. His more than 300 research articles, books and reports have been extensively cited both by researchers and in federal and state policy documents, and have been referenced by more than 7900 papers in the scientific and medical literature. His scientific papers include widely-cited studies on safety of psychotropic medication in children and other populations. He is a frequent adviser to federal and state health agencies, congressional committees and foundations, and has served on many NIH and AHRQ study sections and advisory committees. Dr. Crystal's recent work includes directing a major FDA/AHRQ funded multicenter study of comparative safety and effectiveness of antipsychotic drugs in children, adults and the elderly, and a study for the Institute of Medicine on ADHD diagnosis and treatment. Dr. Crystal's work in comparative safety also includes the development of consensus treatment guidelines for maladaptive aggression in youth, and external review of Texas' prescribing parameters for foster care youth. This year, Dr. Crystal became the first investigator in New Jersey to be awarded a grant from the Patient-Centered Outcomes Research Institute (PCORI), for a 3-year, 4-state study on "Comparative Effectiveness of State Psychotropic Oversight Systems for Children in Foster Care."



Marian F. Earls, MD, MTS, FAAP

Dr. Earls is the Director of Pediatric Programs for Community Care of North Carolina, and was lead on the state CHIPRA Quality Demonstration Grant (2010 - 2015). From 1994 to July 2012 she was the Medical Director of Guilford Child Health, a large, non-profit, private Pediatric practice that was the pediatric division of Triad Adult and Pediatric Medicine in Greensboro, North Carolina and served families at or below 200% of the Federal Poverty Level. She is board-certified in both General Pediatrics and Developmental and Behavioral Pediatrics. She is a Clinical Professor of Pediatrics for the University of North Carolina Medical School.

Dr. Earls also is Medical Director of the Neonatal Follow-up Clinic (multidisciplinary) for the Level III NICU at Women's Hospital in Greensboro. Dr. Earls is a Past President of the North Carolina Pediatric Society (President 2008-2010). She was chair of the Mental Health/School Health Committee for NCPS until 2011. She has been a member of the Committee on the Psychosocial Aspects of Child and Family Health of the AAP, and was the lead author on the committees Clinical Report "Incorporating Recognition and Management of perinatal and postpartum Depression into Pediatric Practice," (PEDIATRICS, November 2010). She is a liaison from the AAP to AACAP (American Academy of Child and Adolescent Psychiatry). She is a member of the Executive Committee of the AAP's Council on Early Childhood. She is Chair of the Mental Health Leadership Work Group of the AAP that is charged with national dissemination of mental health integration in primary care pediatrics.



Robert Hilt, M.D.

Dr. Robert Hilt is an Associate Professor of Psychiatry at the University of Washington and Seattle Children's Hospital. He was trained as a general pediatrician at the University of Iowa, and as an adult and child psychiatrist at the University of Massachusetts. Dr. Hilt has worked as a primary care pediatrician and as a pediatric hospitalist before his current career as a child psychiatrist. Dr. Hilt is the Program Director for the Partnership Access Line, a child mental health consultation service for primary care providers in both Wyoming and Washington. He is the Program Director for the Medicaid psychiatric Medication Second Opinion Programs of Wyoming, Washington and Alaska, and MDT Consult Service in Wyoming. He serves as a co-chair on the Committee on Collaboration with Medical Professions with the American Academy of Child and Adolescent Psychiatry, has served as the Mental Health Editor for the American Academy of Pediatrics' PREP-Self Assessment, and serves on the editorial boards for both *Pediatric Annals* and *Psychiatric Annals*.



Kelly Kelleher, M.D.

Dr. Kelleher is Professor of Pediatrics, Psychiatry and Public Health in the Colleges of Medicine and Public Health at The Ohio State University, Vice President of Community Health and Services Research at Nationwide Children's Hospital, and Center Director in the Center for Innovation in Pediatric Practice at The Research Institute at Nationwide Children's Hospital in Columbus, Ohio. He is a pediatrician and health services researcher focused on improving policy for, and the practice of, pediatric care for high risk children adversely affected by poverty, violence, neglect, alcohol, drug use or mental disorders. He serves or has served on several committees for the National Academy of Medicine and the American Academy of Pediatrics. His research has been continuously funded by NIH for decades, and he is now the PI on projects from NIMH, AHRQ, and CMS/CMMI. He is involved in strategy development for the Nationwide Children's Healthy Neighborhood, Healthy Family zone focusing on collaborative efforts with neighborhood leaders, community agencies and related partnerships to improve housing, employment, schools and safety on the Near South Side of Columbus.



Robert A. Kowatch, MD, Ph.D.

Dr. Kowatch is Professor of Psychiatry at The Ohio State University and Nationwide Children's Hospital in Columbus, OH. He completed an internship in internal medicine at The Graduate Hospital of the University of Pennsylvania in Philadelphia, a residency in general psychiatry at the Hospital of the University of Pennsylvania and a fellowship in child and adolescent psychiatry at Hahnemann University. In 2006 he completed a Ph.D. in Cognition and Neuroscience at the University of Texas at Dallas. Dr. Kowatch has authored or co-authored more than 100 articles, 14 book chapters, and two books. He has published in the areas of the diagnosis and treatment of children and adolescents with bipolar disorders, sleep disorders and depression. His articles have been published in the Journal of American Academy of Child and Adolescent Psychiatry, Neuropsychopharmacology, Archives of General Psychiatry, and Journal of Child Neurology, among others. His clinical and research interests are in pediatric mood and sleep disorders.



Larry S. Marx, M.D.

Dr. Marx is a Board certified General and Child/Adolescent psychiatrist who has held administrative and clinical leadership positions in public, academic and non-profit organizations over the past twenty seven years. He is currently the Group Health's Behavioral Health Support Services' Operations and Medical Director. In this role, Dr. Marx provides 1) Organization-wide clinical leadership in supporting Group Health in meeting its NCOA HEDIS behavioral health related measures, 2) Overseeing the appropriate provision of behavioral health care in both our group practice as well contracted network service delivery systems through utilization and care management programs for approximately 48,000 Group Health members in any given year, and 3) Providing the medical leadership in the spread and stabilization of a Lean-based management system that supports continuous quality improvement. In addition, Dr. Marx is also providing the behavioral health leadership in promoting and sustaining Group Health's integrated primary care/behavioral health collaborative care model that is strengthened by a fully capitated financing strategy.

Dr. Marx is and has been a member of both state and national psychiatric professional committees. He served for six years as both chairperson and vice chairperson of the Juvenile Justice committee of the American Psychiatric Association. He is a founding member of the American Academy of Child and Adolescent Psychiatry's Work Group on Community-based Systems of Care. Dr. Marx also has an extensive public speaking record at the national and state level on a variety of children & adolescent mental health issues.



Douglas Newton, M.D., M.P.H

Dr. Newton serves as the Clinical Lead for Pediatric Behavioral Health at Kaiser Permanente Care Management Institute, Physician Lead for Behavioral Health with KP Community Benefit, and Regional Specialty Chief of Integrated Behavioral Health and Department Value Advisor for Child Psychiatry at KP Colorado. Dr. Newton is the physician partner overseeing service lines between Behavioral Health and Primary Care including Integrated Pain Service, Child Psychiatry, Developmental Pediatrics, Geropsychiatry, as well as virtual care and therapy imbedded in Primary Care. In addition to an active psychiatric practice, Dr. Newton works closely with KP colleagues to implement Primary Care teen depression screening, standardize ADHD and depression guidelines, and initiate various quality metrics and evidence-based care pathways in Colorado and other Kaiser Regions. Youth mental health well-ness and strength-based approaches continue to be his clinical and public health areas of focus. Dr. Newton received his Medical Degree from the University of Wisconsin - Madison, Masters in Public Health from Yale University and completed psychiatry training at Dartmouth-Hitchcock Medical Center.



Rob Penfold, Ph.D.

Dr. Rob Penfold has a unique perspective on health care. By examining changes in health care use over time and in different regions of the United States, his work develops strategies to optimize health care delivery and patient outcomes. His research addresses practical issues such as how to measure direct and indirect costs of complex diseases like depression.

He is a co-investigator in the Mental Health Research Network (MHRN), a resource for studies on mental health conditions ranging from autism to postnatal depression. He leads the child and adolescent focus group within MHRN. Based at Group Health Research Institute as part of the Health Care Services Research Network, the MHRN is a collaboration among nine nonprofit health care and research systems and is funded by the National Institutes of Health. Dr. Penfold is leading the NIMH-funded trial "Safer Use of Antipsychotics in Youth" which is testing universal "Second Opinions" from child psychiatrists as a means to reduce antipsychotic medication use for disruptive behavior disorders. With his extensive research on mental health services for children and young adults, particularly the use of antipsychotic drugs, he is uniquely qualified to lead these projects.

Before joining GHRI in 2010, Dr. Penfold held research and teaching positions at Nationwide Children's Hospital in Columbus, Ohio; the Winnipeg Regional Health Authority; the Manitoba Centre for Health Policy; and most recently, at Harvard Medical School in the Department of Population Medicine and Harvard Pilgrim Health Care Institute



Adelaide Robb, M.D.

Dr. Robb, a professor of child and adolescent psychiatry at George Washington University and Children's National Health System. She was educated at The Johns Hopkins University School of Medicine for both medical school and her general psychiatry residency. She then did a fellowship at the National Institute of Mental Health in psychiatric genetics, followed by a child and adolescent psychiatry fellowship at George Washington University's Children's National Medical Center. She is board certified in both adult and child and adolescent psychiatry.

She has served her hospital in a variety of settings and sees children and teenagers with a variety of psychiatric disorders in both inpatient and outpatient settings. Her major focus is on psychopharmacology including the study of new medications in children and adolescents with a variety of psychiatric disorders. She has been involved with research in pediatric psychopharmacology for 15 years. She has published more than 30 peer-reviewed manuscripts and book chapters. She has served as principal investigator of over 70 pediatric psychopharmacology trials in children and teenagers. She has served as the PI on three separate IND submissions to the FDA, two led to labeling for adolescents with schizophrenia. She was the site co-PI for the NIMH study Treatment of Early Age Mania (TEAM) and the site PI for the CoLT (Collaborative Lithium Trial) study which was a NICHHD Best Pharmaceuticals for Children Act trial of lithium carbonate for pediatric bipolar disorder.



Kelly Rogalski, M.D.

Dr. Rogalski trained in Child and Adolescent Psychiatry at the University of Michigan, and then began her career at Henry Ford Health System as a senior staff pediatric psychiatrist and medical director of outpatient pediatric psychiatry. She has an interest in teen suicide, program development and integrated behavioral health care. Dr. Rogalski is recognized by her peers as one of Metro Detroit's Hour Magazine "Top Docs" in pediatric psychiatry in 2014 & 2015. She has an outpatient practice at the Henry Ford Columbus Center in Novi.



Benedetto Vitiello, M.D.

Dr. Benedetto Vitiello is a psychiatrist with expertise in psychopharmacology and treatment research. A graduate of the University of Pavia (Italy), he trained in pediatrics, psychiatry and child psychiatry. He is Professor (adjunct) of Psychiatry at the Johns Hopkins University in Baltimore, Maryland. Since 1989, he has been at the National Institute of Mental Health, Bethesda, most recently serving as the chief of the Treatment and Preventive Intervention Research Branch. Dr. Vitiello has authored more than 280 scientific publications in the area of child, adolescent, adult, and geriatric psychiatry. His research has focused on testing the effectiveness and safety of psychiatric treatments.
